An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 in Patients with Advanced Solid Tumors
The purpose of this study is to find the dose of the investigational drug RXDX-105 that can be given safely in patients with advanced solid tumors. RXDX-105 blocks the activities of RET and BRAF -- two proteins that, when altered, can fuel cancer growth. The goal of the expansion phase of this study is to treat patients whose cancers have a mutation or fusion in the genes RET and BRAF.
RXDX-105 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor that continues to grow despite prior therapy.
- At least 3 weeks must pass since completion of prior therapy (2 weeks since prior radiation therapy) and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Alexander Drilon at 646-888-4206.